Improvement in the health of HIV-infected persons in care: Reducing disparities

Clinical Infectious Diseases

Volumn 55, Issue 9, 2012, Pages 1242-1251

  Moore, Richard D ^a   Keruly, Jeanne C ^a   Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; ETHNICITY; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HEALTH CARE DISPARITY; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT CARE; POVERTY; PRIORITY JOURNAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BALTIMORE; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH STATUS DISPARITIES; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84867520947     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis654     Document Type: Article

References (38)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2011. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 November 2011.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60. (Pubitemid 28135961)
3. Buchacz K, Baker RK, Palella FJ, et al.; HOPS Investigators. AIDSdefining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24:1549-59.
4. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-42. (Pubitemid 29509554)
5. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007; 21:1579-89. (Pubitemid 47075479)
6. Centers for Disease Control and Prevention. CDC health disparities and inequalities report-United States, 2011. MMWR Morb Mortal Wkly Rep 2011; 60(suppl):1-124.
7. Hall HI, Hughes D, Dean HD, Mermin HG, Fenton K; Centers for Disease Control and Prevention (CDC). HIV infection-United States, 2005 and 2008. MMWR Surveill Summ 2011; 60(suppl):87-9.
8. Song R, Hall HI, Harrison KM, Sharpte TT, Lin LS, Dean HD. Identifying the impact of social determinants of health on disease rates using correlation analysis of area-based summary information. Public Health Rep 2011; 126(suppl 3):70-80.
9. Centers for Disease Control and Prevention (CDC). HIV infection among injection-drug users-34 states, 2004-2007. MMWR Morb Mortal Wkly Rep 2009; 58:1291-5.
10. Gebo KA, Fleishman JA, Conviser R, et al.; HIV Research Network. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24:2705-15.
11. Maryland Department of Health and Mental Hygiene. Maryland HIV/AIDS epidemiological profile. Fourth quarter 2009. Available at: http://dhmh.state. md.us?AIDS/Data&Statistics?marylandHIVEpiPRofile 12-2009.pdf. Accessed 24 November 2011.
12. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr 1998; 17(suppl 1):S38-41. (Pubitemid 128708058)
13. Centers for Disease Control and Prevention (CDC). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:RR17.
14. Moore RD, Bartlett JB. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis 2011; 53:600-4.
15. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injecting drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-23. (Pubitemid 32549862)
16. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35:46-51. (Pubitemid 38044781)
17. Lemly DC, Shepherd BE, Hulfan T, et al. Race and sex differences in antiretroviral therapy used and mortality among HIV-infected persons in care. J Infect Dis 2009; 199:991-8.
18. Palella FJ, Baker RK, Buchacz K, et al.; HOPS investigators. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 2011; 25:1865-76.
19. Lucas G, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidem 2006; 163:412-20.
20. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol. 2006; 1:280-95. (Pubitemid 44244133)
21. Altice FL, Bruce RD, Lucas GM, et al.; BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011; 56(suppl 1):S22-32.
22. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84:188-94. (Pubitemid 44119095)
23. Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse 2008; 34:161-70. (Pubitemid 351302169)
24. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS 2005; 19:837-9. (Pubitemid 40834758)
25. Braveman P. Health disparities and health equity: concepts and measurement. Ann Rev Public Health 2006; 27:167-94.
26. Rubin M, Cohen CG, Link BG. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. Am J Public Health 2010; 100:1053-9.
27. Levine RS, Rust GS, Pisu M, et al. Increased black-white disparities in mortality after the introduction of lifesaving innovations: a possible consequence of US federal laws. Am J Public Health 2010; 100:2176-84.
28. McGinnis KA, Fine MJ, Sharma RK, et al.; Veterans Aging Cohort 3- Site Study (VACS 3). Understanding racial disparities in HIV using data from the Veterans Aging Cohort 3-site study and VA administrative data. Am J Public Health 2003; 93:1228-33.
29. McLaughlin DK, Stokes CS. Income inequality and mortality in US counties: does minority racial concentration matter? Am J Public Health 2002; 92:99-104. (Pubitemid 36018898)
30. Singh GK. Area deprivation and widening inequalities in US mortality, 1996-1998. Am J Public Health 2003; 93:1137-43. (Pubitemid 38489785)
31. Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep 2002; 117: 233-51. (Pubitemid 35351233)
32. Lansky A, Brooks JT, DiNenno E, Heffelfinger J, Hall HI, Mermin J. Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr 2010; 55(suppl 2):S64-8.
33. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24:2705-15.
34. US Department of Health and Human Services. The Secretary's Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020. Available at: http://www.healthy people.gov/2020/about/DisparitiesAbout. aspx. Accessed 28 November 2011.
35. Millett GA, Crowley JS, Koh H, et al. A way forward: the national HIV/AIDS strategy and reducing HIV incidence in the United States. J Acquir Immune Defic Syndr 2010; 55(suppl 2):S144-7.
36. HIV/AIDS Bureau, Health Resources and Services Administration, US Department of Health and Human Services. Going the distance. The Ryan White HIV/AIDS Program: 20 years of leadership. A legacy of care, August 2010. Available at: http://www.impactmc.net/downloads/samples/writing/Going-the- Distance-20-years-of-the-Ryan-White-HIVAIDS- Program.pdf. Accessed 22 November 2011.
37. Gallant JE, Adimora AA, Carmichael JK, et al. Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of American and the Ryan White Medical Providers Coalition. Clin Infect Dis 2011; 53:1043-50. Available at: http://www.ahrq.gov/ qual/nhdr03/nhdrsum03.htm. Accessed 14 November 2011.
38. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment - United States. Morb Mortal Weekly Rep 2011; 60:1-6.